Interní Med. 2011; 13(11): 436-439

Immunosuppressive drugs in cardiology

doc.MUDr.Ivan Málek, CSc., MUDr.Markéta Hegarová
Klinika kardiologie IKEM, Praha

The aim of the article is to provide a basic information about immunosuppressive drugs and their use in cardiology. The most frequent

indication for immunosuppressants is the prevention and treatment of rejection after cardiac transplantation. Drugs with antiproliferative

effect (m-TOR inhibitors) are also the most frequent ones used in drug-eluting coronary stents, decreasing significanty the

rate of restenosis. Another form of coronary proliferative syndrome, chronic rejection after cardiac transplantation, can be effectively

influenced with systemic aplication of these drugs. Another indication for immunosuppressives present some types of myocarditis and

inflammatory cardiomyopathies. Calcineurin inhibitors may be useful in the prevention of injury after myocardial reperfusion, but this

approach in still experimental.

Keywords: immunosuppressive drugs, cardiac transplantation, myocarditis, drug eluting stent, myocardial reperfusion

Published: November 1, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Málek I, Hegarová M. Immunosuppressive drugs in cardiology. Interní Med. 2011;13(11):436-439.
Download citation

References

  1. Pirk J, Málek I, a kol. Transplantace srdce. Praha: Karolinum, 2008: 287.
  2. Oyer PE, Stinson EB, Jamieson SW, et al. One year experience with cyclosporin A in clinical transplantation. Heart Transplant. 1982; 1: 285.
  3. Martínek V, Matoušovic K, Špatenka J. Objev a užití cyklosporinu v klinické praxi. Praktický lékař 2002; 82: 14-20.
  4. Saudek F. Tacrolimus. Remedia 2006; 16: 61-79.
  5. Groetzner J, Kaczmarek I, Meiser B, et al. Sirolimus and mycophenolate mofetil as calcineurin inhibitor-free immunosuppression in cardiac transplant patient with chronic renal failure. J Heart Lung Transplant, 2004; 23: 770-773. Go to original source... Go to PubMed...
  6. Kauffman HM, Cherikh WS, Cheng Y, et al. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de-novo malignancies. Transplantation 2005; 80: 883-889. Go to original source... Go to PubMed...
  7. Grauhan O, Knosalla C, Ewert R, et al. Plasmapheresis and cyclophosphamide in the treatment of humoral rejection after heart transplantation. J Heart Lung Transplant. 2001; 20: 316-321. Go to original source... Go to PubMed...
  8. Hošková L, Málek I, Šedivý J, a kol. Lékové interakce cyklosporinu A. Cor Vasa 2002; 44: 481-486.
  9. Wojnicz R, Nowalany-Kozielska E, Woiciechowska C, et al. Randomized, placebo-controlled study for immunosuppressive treatment of inflammatory dilated cardiomyopathy: twoyear follow-up results. Circulation 2001; 104: 39-45. Go to original source... Go to PubMed...
  10. Frustaci A, Chimenti C, Calabrese F, et al. Immunosuppressive therapy for active lymphocytic myocarditis. Virological and immunologic profile of responders versus nonrensponders. Circulation 2003; 107: 857-863. Go to original source... Go to PubMed...
  11. Schultheiss HP, Kühl U. What are the current treatment options for myocarditis? Dialogues in Cardiovascular Medicine 2009; 14: 187-193.
  12. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002; 346: 1773-1780. Go to original source... Go to PubMed...
  13. Hradec J, Bultas J, Želízko M. Stabilní angina pectoris. Doporučený diagnostický a léčebný postup ČKS. Cor Vasa 2010; 52: 543-561. Go to original source...
  14. Kobashigawa JA, Moriguchi JD, Laks H, et al. Ten year follow-up of a randomized trial of pravastatin in heart transplant patients. J Heart Lung Transplant. 2005; 24: 1736-1740. Go to original source... Go to PubMed...
  15. Kobashigawa J, Miller L, Renlund D, et al. A randomizedactive-controlled trial of mycophenolate mofetil in heart transplant recipients. Transplantation 1998; 66: 507-515. Go to original source... Go to PubMed...
  16. Eisen HJ, Tuzcu EM, Dorent R. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med. 2003; 349: 847-858. Go to original source... Go to PubMed...
  17. Braunwald E, Kloner RA. Myocardial reperfusion: a double-edged sword? Clin Invest 1985; 76: 1713-1719. Go to original source... Go to PubMed...
  18. Piper HM, Garcia-Dorado D, Ovize M. A fresh look at reperfusion injury. Cardiovasc Res. 1998; 38: 291-300. Go to original source... Go to PubMed...
  19. Duchen MT, McGuinness O, Brown LA, Crompton M. On the involvement of a cyclosporin A sensitive mitochondrial pore in myocardial reperfusion injury. Cardiovasec Res. 1993; 27: 1790-4. Go to original source... Go to PubMed...
  20. Piot C, Croisille P, Staat P. et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med. 2008; 359: 473-481. Go to original source... Go to PubMed...




Internal Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.